Abstract

The invention relates to methods of evaluating the quality of a batch of an herbal composition, the method comprising subjecting a test batch of the herbal composition to one or more biological analysis methods and comparing the results derived from the test batch to the results of a known batch of herbal composition which has a known in vivo effect.

IPC Classes  ?

• A61K 36/539 - Scutellaria (skullcap)
• A61K 36/484 - Glycyrrhiza (licorice)
• A61K 36/65 - Paeoniaceae (Peony family), e.g. Chinese peony
• A61K 36/725 - Ziziphus, e.g. jujube

Abstract

Described herein are antibodies having pan-antiviral activity. In certain embodiments, the antibodies recognize glycosylation patterns specific to viral proteins, but not found on host proteins. Also described herein are methods of preventing, treating, and/or ameliorating viral infections using the antibodies of the disclosure.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

An ultra-high vacuum instrument, comprising a vacuum chamber, a sample storage stage, a non-evaporable getter and/or ion pump connected to the vacuum chamber to reduce the ambient pressure in the vacuum chamber, and at least one vacuum port including connection hardware adapted to connect to a sputtering gun for cleaning a sample surface or an evaporator for supplying material to grow a film on a sample. The sample storage stage, in some embodiments, includes a first sample parking position, a heating element adapted to apply heat to a sample loaded in the first sample parking position, one or more second sample parking positions, and a thermal insulating plate positioned to insulate the second sample parking positions from heat generated by the heating element.

IPC Classes  ?

• C30B 25/02 - Epitaxial-layer growth
• C30B 25/06 - Epitaxial-layer growth by reactive sputtering
• C30B 25/08 - Reaction chambersSelection of materials therefor
• C23C 14/56 - Apparatus specially adapted for continuous coatingArrangements for maintaining the vacuum, e.g. vacuum locks
• C23C 14/24 - Vacuum evaporation
• C23C 14/34 - Sputtering
• H01J 37/20 - Means for supporting or positioning the object or the materialMeans for adjusting diaphragms or lenses associated with the support
• H01J 41/12 - Discharge tubes for evacuating by diffusion of ions, e.g. ion pumps, getter ion pumps
• H01J 7/18 - Means for absorbing or adsorbing gas, e.g. by gettering
• H01J 19/70 - Means for obtaining or maintaining the vacuum, e.g. by gettering
• H01J 41/16 - Discharge tubes for evacuating by diffusion of ions, e.g. ion pumps, getter ion pumps with ionisation by means of thermionic cathodes using gettering substances

Abstract

Described herein is an mRNA molecule including a 5'-cap analog, a 5'-untranslated region (5'-UTR), and a coding sequence. The translational enhancer sequence, when combined with the 5'-cap analog, increases a translational efficiency of the mRNA. Also described herein is a method of modulating a translational efficiency of an mRNA molecule based on the construction of the mRNA molecule herein, as well as a method of expressing a polypeptide or a protein using the mRNA molecule herein.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

Topical formulations have been developed which have been demonstrated to reduce ultraviolet ("UV")-induced cyclobutane pyrimidine dimer ("CPD") formation in a human clinical trial. The formulation includes all natural, non-toxic compounds which can be utilized in sunscreens, cosmetics and hair conditioners to protect from ultraviolet radiation. A preferred embodiment of the formulation contains 10% Ferulic Acid, 10% Diosmin, 5% Cytisine and 5% Resveratrol. A method of screening for compounds that are safe and effective to reduce UV-induced CPD formation also has been developed.

IPC Classes  ?

• A61K 8/34 - Alcohols
• A61K 8/365 - Hydroxycarboxylic acidsKetocarboxylic acids
• A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
• A61K 8/60 - SugarsDerivatives thereof
• A61Q 17/04 - Topical preparations for affording protection against sunlight or other radiationTopical sun tanning preparations
• G01N 21/25 - ColourSpectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
• G01N 21/33 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light

Abstract

Administration of recombinant or biologically-isolated renalase has been shown to treat certain diseases and conditions. Stable synthetic peptides exhibiting renalase agonist activity are highly desirable. Disclosed are compositions comprising modified renalase agonist peptides that display increased in vitro and/or in vivo half-life, and methods for their use in treating diseases such as ischemic and toxic organ injury.

IPC Classes  ?

• A61K 38/44 - Oxidoreductases (1)
• C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes

Abstract

An electrolytic device, photoelectrode, and method for inducing an electrochemical reduction of a feed gas, comprising an anode and a hybrid cathode, the hybrid cathode comprising a cathode, a microporous layer disposed on one side of the cathode; a cathode catalyst positioned on the surface of the microporous layer, a gas channel fluidly connected to the microporous layer, containing a quantity of a feed gas, an electrolyte channel fluidly connected to the cathode catalyst containing a quantity of electrolyte, wherein the hybrid cathode is configured to induce an electrochemical reaction in the feed gas to produce methanol, and wherein the cathode catalyst comprises a compound represented by General Formula (I).

IPC Classes  ?

• C25B 11/04 - ElectrodesManufacture thereof not otherwise provided for characterised by the material
• C25B 11/051 - Electrodes formed of electrocatalysts on a substrate or carrier
• C25B 11/091 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of at least one catalytic element and at least one catalytic compoundElectrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of two or more catalytic elements or catalytic compounds
• C25B 11/02 - ElectrodesManufacture thereof not otherwise provided for characterised by shape or form

Abstract

Methods of treating autoimmune skin diseases and disorders are provided. The methods typically include administrating to a subject with an autoimmune skin disease or disorder an effective amount of a hypoxia-inducible factor-1 (HIF-1) inhibitor. In preferred embodiments, the autoimmune disease is mediated at least in-part by T cells, particularly skin-infiltrating T cells. In some embodiments, the subject has cutaneous lupus (e.g., discoid cutaneous lupus, subacute cutaneous lupus, acute cutaneous lupus), pemphigus, pemphigoid, epidermolysis bullosa acquisita, vitiligo, lichen planus, lichen sclerosus, dermatomyositis, alopecia areata, or Sjögren's syndrome. HIF-1 inhibitors and pharmaceutical compositions including the same for use in the disclosed methods are also provided. The HIF-1 inhibitor can be, for example, a small molecule, functional nucleic acid, or inhibitory polypeptide or protein. The pharmaceutical composition can be formulated to suitable for the type and mode of administration, e.g., systemically or locally to skin effected by the autoimmune disease.

IPC Classes  ?

• A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
• A61K 38/12 - Cyclic peptides
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

A computer-implemented method of increasing appointment attendance comprises providing a processor and a non-transitory memory including computer program code for one or more programs, the memory and the computer program code configured to, with the at least one processor, perform steps comprising obtaining an appointment data structure, comprising an attendee and a corresponding appointment for the attendee, obtaining a set of population data, obtaining a set of appointment data, obtaining a set of external data, obtaining environmental data, inferring, using the population data, the appointment data, the external data, and the environmental data in a machine learning algorithm, a probability that the attendee will attend the appointment, and when the probability of attendance is below a threshold, performing a mitigation step to increase the probability that the attendee will attend the appointment. A system for increasing appointment attendance and a non-transitory computer-readable medium containing computing instructions are also described.

IPC Classes  ?

• G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms

Abstract

A computer-implemented method of increasing likelihood of appointment completion comprises providing at least one processor; and at least one non-transitory memory including computer program code, configured to perform steps comprising obtaining an appointment data structure comprising an attendee and a corresponding appointment for the attendee, obtaining data comprising at least one of a set of population data, a set of appointment data, a set of external data, or environmental data, wherein the data comprises at least two different formats, standardizing the at least two different formats of data, inferring, using the standardized data in a machine learning algorithm by the at least one processor and the at least one non-transitory memory, a probability that the attendee will complete the appointment, and when the probability of completion is below a threshold, performing a mitigation step to increase the probability that the attendee will complete the appointment.

IPC Classes  ?

• G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
• G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
• G16H 80/00 - ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring

Abstract

The compounds of Formula I described herein regulate activity of JAK2 by specifically binding to the JAK2 pseudokinase domain, JH2, and are useful as therapeutic agents in the treatment or amelioration of myeloproliferative disorders. Also provided herein are methods of treating myeloproliferative disorders, and methods of making compounds of Formula I.

IPC Classes  ?

• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 31/4196 - 1,2,4-Triazoles
• A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07D 249/14 - Nitrogen atoms
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 487/04 - Ortho-condensed systems

Abstract

The invention provides microglial cell comprising cortical organoid cultures, methods of generating the same and methods of use thereof for identifying therapeutic agents.

IPC Classes  ?

• C12N 5/079 - Neural cells
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Quantum systems and techniques are described to generate fault tolerant cluster states for use in quantum computation, quantum networking, and other applications. The systems and techniques include initializing states in first qubits and generating initial resource states by performing first Pauli product measurements on sets of X-type and/or Z-type qubits of the first qubits, the initial resource states comprising qubit cluster states comprising at least three qubits. The final cluster state may then be generated by fusing two or more initial resource states, the fusing comprising performing second Pauli product measurements between qubits of two or more of the initial resource states.

IPC Classes  ?

• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control

Abstract

Described herein are methods and compositions useful to reduce (partially/inhibit or completely—prevent) skin cancer development in an individual in need thereof.

IPC Classes  ?

• A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Described herein is a probe for monitoring specific RNA splicing events, with utility for identifying molecular modulators of RNA splicing. The probe includes a nucleic acid, a first fluorescent element attached to a first end of the nucleic acid, and a second fluorescent element attached to a second end of the nucleic acid. The fluorescence signal of the probe changes when the probe hybridizes with either a pre-splicing RNA molecule or a splicing product. Also described herein is a method of monitoring RNA splicing and a method of screening of modulators of RNA splicing using the probe.

IPC Classes  ?

• C12Q 1/6818 - Hybridisation assays characterised by the detection means involving interaction of two or more labels, e.g. resonant energy transfer
• C12Q 1/6895 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae

Abstract

Described is small molecule N-(l-isopropylpiperidin-4-yl)-6-methoxy-2-morpholino-7- (3-(pyrrolidin-l-yl)propoxy)quinolin-4-amine)) (MS 1262) that inhibits methyltransferases G9a/GLP. This inhibitor can be used for the treatment of patients with G9a/GLP related diseases such as Alzheimer's Disease and Prader-Willi Syndrome.

IPC Classes  ?

• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

It has been established that the presence of RIPLs is associated with higher prevalence of stroke, and especially in patients with atrial fibrillation. Enhanced methods for the detection and quantitation of retinal ischemic perivascular lesions (RIPLs) from commonly used OCT scans which are widely used in optometry and ophthalmology clinics are described. Systems and methods to characterize disease state and risk of stroke based on the identification and quantitation of RIPLs in the eyes of patients having atrial fibrillation have been developed. Methods of using information obtained according to the described methods to guide patient stratification for anticoagulation therapy are provided. Methods of identifying RIPLs from OCT scans are provided.

IPC Classes  ?

• A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
• A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 3/12 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes

Abstract

Described herein is a stable colibactin derivative, or a salt, solvate, isotopically labelled derivative, stereoisomer, tautomer, or geometric isomer thereof, or any mixtures thereof. Also described herein is a method of alkylating a DNA molecule, a method of forming a DNA interstrand cross-link (ICL), as well as a method of preventing, treating, and/or ameliorating cancer.

IPC Classes  ?

• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61P 35/00 - Antineoplastic agents
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings

Abstract

Dkk1Dkk1+ progenitors transiently amplify to become quiescent dermal condensate cells by the spatiotemporal patterning of Wnt/β-catenin and sonic hedgehog ("SHH") signaling gradients. Together, they deterministically coordinate a rapid transition from proliferation to quiescence, cell fate specification, and morphogenesis. This is useful for screening to discover compounds that can be administered to hair follicles to stimulate hair growth (new hair follicles) and restore hair follicle size. These agonists of Wnt and SHH are formulated for application to skin to grow hair.

IPC Classes  ?

• A61K 31/4436 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
• A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia
• A61K 8/00 - Cosmetics or similar toiletry preparations
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61Q 7/00 - Preparations for affecting hair growth
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances

Abstract

A drainage device includes an elongate flexible conduit comprising a proximal end opening, a distal end opening and a lumen disposed therebetween. A multi-layer distal portion coaxially surrounding the lumen and having a porous outer surface layer, a porous interior layer and an intermediate absorbent layer therebetween. A drainage system and a device and method for treating dysphagia are also disclosed.

Abstract

The present invention is directed to methods of sensitizing tyrosine kinase inhibitor (TKI)-resistant cancer cells in a subject using a SWI/SNF complex modulator.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

Described herein is a method of reversing or preventing a formation or enlargement of an axonal spheroid. The method includes introducing into a neuron affected by formation or enlargement of the axonal spheroid a compound that downregulates PLD3 expression level or activity. Also described herein is a method of treating or preventing a neurodegenerative condition in a subject in need thereof. The method includes administering to the subject a compound that downregulates PLD3 expression level or activity in a neuron cell affected by the neurodegenerative condition. Further described herein is a pharmaceutical composition for treating a neurodegenerative condition in a subject. The pharmaceutical composition includes a compound that downregulates PDL3 expression level or activity in a neuron cell affected by the neurodegenerative condition; and a pharmaceutically acceptable carrier.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/90 - Stable introduction of foreign DNA into chromosome

Abstract

The current disclosure includes a modular vaccine platform. Also included are monkeypox vaccines that protect against pathogenic monkeypox species, as well as their variants. The vaccines typically include a modified mRNA encoding at least one immunogen, such as a viral envelope protein, cell surface binding protein, or a biologically effective/significant fragment thereof. The mRNA can be encapsulated into lipid nanoparticles or other carriers and formulated as pharmaceutical compositions that can be used to generate an immune response to pathogens, including monkeypox virus, in a subject.

IPC Classes  ?

• A61K 39/275 - Poxviridae, e.g. avipoxvirus
• C12N 15/86 - Viral vectors

Abstract

Methods of isolating and sequencing aberrant expansion-specific RNA sequences using antisense oligonucleotides (ASO) specific for repeat-containing RNAs have been established. The methods isolate repeat-containing RNAs from RNA using hybridization probes specific for repeat-containing sequences. Typically, RNA capture is performed by preferential hybridization of repeat-containing RNAs to a multiplicity of immobilized probes. The methods isolate expansion-specific RNAs and determine the sequences of aberrant splice variants associated with diseases and disorders. In other forms, the methods identify small molecules that selectively target the pathological splice variant transcripts. In some forms, the methods provide expansion-specific ASOs that specifically target and eliminate the pathological splice variant transcripts in vivo. Compositions of ASOs that specifically target and eliminate the pathological splice variant transcripts are also provided.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C12Q 1/6897 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters

Abstract

A bioadhesive nanoparticle (BNP) for long-lasting local drug delivery to treat cancer was developed. The bioadhesive nanoparticles (BNP) are composed of biodegradable polymer such as poly(lactic acid)-hyperbranched polyglycerol (PLA-HPG), encapsulating a chemotherapeutic such as camptothecin (CPT). Nanoparticles (NPs) of PLA-HPG are non-adhesive NPs (NNPs), which are stealthy in their native state, but conversion of the vicinal diols of HPG to aldehydes confers the ability to form strong covalent bonds with amine-rich surfaces. The formulation is administered in combination with immunostimulatory molecules such as CPG and shows unexpectedly better killing of cancer cells.

IPC Classes  ?

• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61K 9/51 - Nanocapsules
• A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61P 35/00 - Antineoplastic agents

Abstract

Various semiconductor structures containing buried tunnel junctions or aperture regions are described. Further disclosed are methods for preparing and using such semiconductor structures which can be used, for example, in optoelectronic devices, such as vertical cavity surface emitting lasers (VCSELs), which can emit at long wavelengths.

IPC Classes  ?

• H01S 5/183 - Surface-emitting [SE] lasers, e.g. having both horizontal and vertical cavities having only vertical cavities, e.g. vertical cavity surface-emitting lasers [VCSEL]
• H01S 5/30 - Structure or shape of the active regionMaterials used for the active region

Abstract

e.g.e.g., mRNA) to cells, tissues, and/or organs with longer circulation time after systemic injection.

IPC Classes  ?

• C08G 83/00 - Macromolecular compounds not provided for in groups
• A61K 9/51 - Nanocapsules
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• C08G 61/08 - Macromolecular compounds containing only carbon atoms in the main chain of the macromolecule, e.g. polyxylylenes only aliphatic carbon atoms prepared by ring-opening of carbocyclic compounds of carbocyclic compounds containing one or more carbon-to-carbon double bonds in the ring

Abstract

Poly arid perfluoroalkyl substances (PFAS) are toxic, ubiquitous contaminants in the environment along with drinking and waste water systems. Current treatment approaches struggle to effectively treat PEAS molecules without generating large amounts of toxic waste or requiring large energy and/or material inputs. With addition of alcohol such as decanol alone, PFAS such as water-soluble perfluorooctanoic acid (PFOA), can be transformed into a water-insoluble, fluorinated ester(s) that precipitate out of solution, facilitating self-removal. Highly hydrophobic fluorinated tails allow for esterification to proceed in water without the addition of any surfactant.

IPC Classes  ?

• C02F 1/54 - Treatment of water, waste water, or sewage by flocculation or precipitation of suspended impurities using organic material
• C02F 101/36 - Organic compounds containing halogen

Abstract

The present disclosure generally relates methods and compositions comprising VEGF-D, which methods and compositions can be used in the treatment of respiratory disorders. In some instances, the methods and compositions can be used for treating acute lung injury (ALI) or acute respiratory distress syndrome (ARDS).

Abstract

Provided herein are methods of training an algorithm for adaptive predictive enrichment of a randomized controlled trial (RCT). The method includes providing an RCT with at least one primary outcome; defining an interim analysis timepoint; at the interim analysis timepoint, defining individualized estimates of the effects of a studied intervention for the primary outcome, as compared to a control arm, through iterative analysis; and training a machine-learning algorithm to identify one or more signatures of individualized treatment response in a treatment group as compared to a control group; where the one or more signatures of individualized treatment response are used to recommend predictive enrichment for subsequent RCT enrollment. Also provided herein is a method of adaptive predictive enrichment of a RCT including applying the algorithm trained above.

IPC Classes  ?

• G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G06T 7/00 - Image analysis

Abstract

The present invention provides cationic polymeric nanoparticles, and nanoparticle formulations thereof. The invention also provides methods for preparing cationic polymeric nanoparticles, and methods of treating diseases, reducing tumor growth, and increasing uptake of a therapeutic agent by a tumor cell in a subject in need thereof.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 9/51 - Nanocapsules
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine

Abstract

The disclosure provides compositions and methods for identifying a cancer associated with an RASGRF1 gene fusion in a subject. The disclosure also includes methods of treating a subject who has been pre-selected by detecting an RASGRF1 gene fusion in a sample obtained from the subject.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 35/00 - Antineoplastic agents
• C12Q 1/6869 - Methods for sequencing
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

Techniques are described for implementing a class of multimode bosonic codes that protect against errors within an ancilla qubit coupled to a bosonic system, that can be realized experimentally. A logical qubit state is represented by the states of multiple different modes of one or more bosonic systems, which may include multiple modes of a single bosonic system and/or single modes from multiple bosonic systems. Techniques for correcting errors are also described. In particular, a series of operations are described that autonomously detect and correct errors by repeatedly performing a sequence of operations that are each applied to the multiple bosonic modes and/or to the ancilla qubit that is coupled to each of the bosonic modes. The codes allow ancilla errors to propagate to the modes of the bosonic system as correctable errors, where they can be corrected, instead of presenting as logical errors in the ancilla qubit.

IPC Classes  ?

• G06N 10/70 - Quantum error correction, detection or prevention, e.g. surface codes or magic state distillation
• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control

Abstract

Provided herein are compositions and methods for high resolution spatial transcriptomic and epigenomic co-profiling of a biological sample.

IPC Classes  ?

• C12Q 1/6855 - Ligating adaptors
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• C12Q 1/6804 - Nucleic acid analysis using immunogens
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/6869 - Methods for sequencing
• G01N 1/30 - StainingImpregnating

Abstract

Provided herein are methods for communicating data between nodes in a computer system and distributed systems of computer architectures. The methods include generating a hash based upon a data set, communicating the hash to one or more nodes, comparing the communicated hash to stored hashes at the one or more nodes, and communicating the data set when matching hashes are detected. The system includes two or more processing elements configured to communicate data according to the methods above.

IPC Classes  ?

• G06F 9/50 - Allocation of resources, e.g. of the central processing unit [CPU]
• G06F 1/3296 - Power saving characterised by the action undertaken by lowering the supply or operating voltage

Abstract

Provided is an adsorbent for removing perfluoroalkyl and polyfluoroalkyl substances from an aqueous solution, including perfluoro-octanoic acid (PFOA), perfluoro-octane sulfonate (PFOS), shorter-chained perfluoroalkyl and polyfluoroalkyl substances, and combinations of foregoing. The adsorbent includes iron oxide nanocrystals, wherein the absorbent has an adsorption capacity for PFOA of at least 5000 mg/g or an adsorption capacity for PFOS of at least 25,000 mg/g. Also provided are methods of removing contaminants from an aqueous solution, wherein the contaminants include perfluoroalkyl and polyfluoroalkyl substances.

Abstract

Methods and compositions for treating or preventing non-viral tick-borne diseases and symptoms thereof by administering a long half-life 8-aminoquinoline, such as tafenoquine, are disclosed. Kits including a means for testing for a non-viral tick-borne disease and/or symptoms thereof and a long half-life 8-aminoquinoline, such as tafenoquine, are disclosed.

IPC Classes  ?

• A61K 31/47 - QuinolinesIsoquinolines
• A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Abstract

The present invention provides methods for bioprinting collagen and extracellular matrix-based bioinks, and articles such as engineered tissues, comprising the bioinks. In other aspects, the present invention relates to a bioprinting system including a 3D bioprinter with a nozzle, at least one bioink, a support bath solution, wherein the support bath solution comprises PEG (polyethylene glycol) and agarose.

IPC Classes  ?

• B29C 64/209 - HeadsNozzles
• B33Y 70/10 - Composites of different types of material, e.g. mixtures of ceramics and polymers or mixtures of metals and biomaterials

Abstract

Provided herein, in one aspect, is a method of preventing or delaying the onset of clinical type 1 diabetes (T1D), comprising: providing a non-diabetic subject who is at risk for T1D; administering a prophylactically effective amount of an anti-CD3 antibody to the non-diabetic subject; and determining, prior to or after the administering step, that the non-diabetic subject has more than about 5% to more than about 10% TIGIT+KLRG1+CD8+ T-cells in all CD3+ T-cells, which is indicative of successful prevention or delay of the onset of clinical T1D.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Provided are digitally-implemented methods of treating a mental health issue in a subject. The methods include digitally delivering a standardized assessment to the subject; analyzing data collected from the standardized assessment; identifying an evidence-based treatment pathway based upon the analysis of the data; and administering the evidence-based treatment pathway to the subject.

IPC Classes  ?

• G16H 20/70 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
• G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
• A61B 5/16 - Devices for psychotechnicsTesting reaction times

Abstract

Aspects of the present invention relate to a system including a transformer encoder with a compression layer, a transformer decoder with an expansion layer, the transformer encoder configured to transform one or more inputs into a control latent vector, a noise injection element configured to add noise to the control latent vector to create a noisy latent vector, a weighting element configured to add one or more weightings to the control latent vector to create an exact latent vector, and the transformer decoder configured to transform the noisy latent vector and exact latent vector into an output.

IPC Classes  ?

• G16C 20/70 - Machine learning, data mining or chemometrics
• G06F 30/28 - Design optimisation, verification or simulation using fluid dynamics, e.g. using Navier-Stokes equations or computational fluid dynamics [CFD]

Abstract

Described herein is method of identifying cis-regulatory element of translation. The method includes: translating a plurality of mRNA molecules, each comprising a potential cis-regulatory element, with ribosomes to obtain a mixture; generating from the initial mixture an enriched mixture comprising mRNA molecules being translated, the ribosomes, and partial translation products being produced by the ribosomes from the mRNA molecules, according to affinity of the partial translation products to a binding partner thereof; sequencing the mRNA molecules present in the enriched mixture; determining an abundance of each mRNA molecule present in the enriched mixture; and identifying cis-regulatory elements of translation based on the determined abundance of each of the plurality of mRNA molecules. Also described herein is a method of determining translational efficiency of an mRNA molecule that includes similar steps.

Abstract

Provided herein are methods of developing a meta-modeling framework for ligand-protein binding affinity prediction by integrating empirical scoring function-based docking and deep learning-based regression outputs through linear and non-linear machine learning models. Thus, empirical docking models and deep learning models were used as base models data. By taking predictions from those base models, machine learning regression models were developed as meta-models. These meta-models significantly improve binding affinity prediction over individual base models and achieve comparable performance to other structure-based deep learning models.

IPC Classes  ?

• G16B 15/30 - Drug targeting using structural dataDocking or binding prediction
• G06N 3/0985 - Hyperparameter optimisationMeta-learningLearning-to-learn
• G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
• G06N 3/02 - Neural networks

Abstract

Provided herein are methods of training and building algorithms to predict stroke etiology. The method of training an algorithm to predict stroke etiology includes processing electronic health records (EHRs) in a derivation dataset, the processing including extracting clinical variables from the EHRs by detecting concept unique identifiers (CUIs) through natural language processing (NLP), and extracting other covariates from the EHRs through regular expression, wherein the clinical variables and other covariates form a training dataset; training two or more base models with the training set to form two or more trained base models, the base models selected from the group including Random Forests (RF), XGBoost (XGB), support vector classifier (SVC), and logistic regression (LR); refining the two or more trained base models using hyperparameters to form two or more refined base models; and building an ensemble model with the two or more refined base models. Also provided herein are articles and methods of predicting ischemic stroke etiology using the trained algorithm.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/318 - Heart-related electrical modalities, e.g. electrocardiography [ECG]
• G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
• G06F 18/214 - Generating training patternsBootstrap methods, e.g. bagging or boosting

Abstract

Disclosed are compounds and methods of treating, ameliorating, and/or preventing cancers, including cancers that are MGMT deficient regardless of their MMR status, and particularly compounds and methods of treating, ameliorating, and/or preventing cancers that are both MGMT and MMR deficient or that are MGMT deficient and resistant to treatment with temozolomide.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61P 35/00 - Antineoplastic agents

Abstract

PC1-CTT polypeptides for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) are provided and can be or include PC1-CTT (SEQ ID NO:1) or a functional fragment or variant thereof. In some embodiments, the PC1-CTT polypeptide is a fusion protein or conjugate further including a functional element such as a protein transduction domain, fusogenic polypeptide, targeting signal, or expression and/or purification tag. Nucleic acids encoding the disclosed PC1-CTT polypeptides and other therapeutic proteins are also provided. In some embodiments, the nucleic acid encodes a TOP or TOP-like motif. The nucleic acids can be RNA or DNA, and can be, for example, a vector such as a plasmid or viral vector, or an mRNA. Methods of treatment are provided and typically include administering a subject in need thereof an effective amount of a disclosed polypeptide or nucleic acid.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

An imaging method calculates T2 maps using only data from a T2w image scan. The imaging system is used in conjunction with an MRI system that includes a magnet housing, a superconducting magnet, shim coils, RF coils, receiver coils, a patient support, and measurement circuitry producing data used to reconstruct images displayed on a display. The measurement circuitry integrates either expanding-constrained alternating minimization for parameter mapping or expanding-constrained alternating minimization for parameter mapping with projected gradient descent.

IPC Classes  ?

• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• G01R 33/48 - NMR imaging systems
• G01R 33/50 - NMR imaging systems based on the determination of relaxation times
• G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques

Abstract

Described herein is a non-natural mRNA molecule, which includes a non-natural cisregulatory element that modulates the translational efficiency of the mRNA molecule. Also described herein is a method for modulating mRNA translational efficiency.

Abstract

A system for integrated lifestyle medicine tracking and digital therapy comprises a central computing system comprises a device interface subsystem, a user data interface subsystem, a data visualization engine, and a set of instructions, which when executed by the processor, perform steps comprising collecting a first data stream from the at least one sensor via the device interface subsystem, collecting a first user-reported data stream from the at least one user via the user data interface subsystem, calculating a probability of at least one lifestyle risk factor from the first data stream and the first user-reported data stream, and presenting the user with at least one intervention to mitigate the at least one lifestyle risk factor. A method for integrated lifestyle medicine tracking and digital therapy is also disclosed.

IPC Classes  ?

• G16H 10/00 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data
• G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance

Abstract

The present invention relates to fiber jamming systems capable of tuning tensile stiffness of soft systems within seconds without the use of high voltage or temperature changes. The systems employ segmented fibrils of interspersed segments of stretchable and non-stretchable materials. Applying a vacuum to the fibrils in an enclosed volume elicits a large interfacial shear resistance to tensile displacement. In the absence of a vacuum, the fibrils are free to stretch and bend in any direction.

IPC Classes  ?

• D01F 8/14 - Conjugated, i.e. bi- or multicomponent, man-made filaments or the likeManufacture thereof from synthetic polymers with at least one polyester as constituent
• A41D 19/00 - Gloves
• D01D 5/42 - Formation of filaments, threads, or the like by cutting films into narrow ribbons or filaments or by fibrillation of films

Abstract

A scanning electron microscopy (SEM) system performs subvoxel microscopy with a probe and detector. The probe directs incoming probe electrons at a sample with an energy and a direction. The detector detects electrons scattered by the sample and generates a two-dimensional energy profile map of the detected electrons. The system may determine subvoxel information including features of the sample smaller than a size of the probe using the energy and direction and the two-dimensional energy profile map. The system may determine three-dimensional subvoxel information of the sample. The system may be a focused ion beam scanning electron microscopy (FIB-SEM) system with an emitter directing a FIB at the sample to separate layers thereof. For each of multiple layers, the system may obtain the energy and direction and generate the two-dimensional energy profile map. The system may generate three-dimensional subvoxel volume information of the sample thicker than individual layers.

Abstract

In one aspect, the invention provides a protein capture membrane comprising a first side and a second side and a plurality of interstices extending contiguously from the first side to the second side, wherein the interstices are coated with a protein-reactive coating; and the porous substrate comprises nanoporous alumina or porous glass. In another aspect the invention provides a method of detecting a protein of interest in a plurality of proteins.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• B01D 57/02 - Separation, other than separation of solids, not fully covered by a single other group or subclass, e.g. by electrophoresis
• B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or propertiesManufacturing processes specially adapted therefor characterised by their properties
• B01D 69/10 - Supported membranesMembrane supports

Abstract

It has been determined that differential methylation at CpG loci can be used to determine the severity of lupus nephritis (LN). Thus, differentially methylated CpG loci (also referred to herein as biomarkers), as well as methods of detecting methylation at the biomarkers are provided, as are their use to determine the severity of LN and inform treatment. In particular, the differential methylation is useful in distinguishing patients with class II LN from patients suffering from LN of classes III - VI and thereby determining whether the patient should be given immunosuppressants.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

Described herein are methods of modulating mRNA translational efficiencies with translational enhancers or silencers that affects ribosomal retention. Also described herein are mRNA molecules including translational enhancers or silencers, as well as modified nucleobases. Also described herein are methods of constructing an mRNA molecule for producing a therapeutic peptide or a therapeutic protein with the identified enhancers.

Abstract

The present invention relates to bifunctional compounds, which find utility to degrade and (inhibit) TBK1. In particular, the present invention is directed to compounds, which contain on one end an E3 ubiquitin ligase binding moiety which binds to an E3 ubiquitin ligase and on the other end a moiety which binds TBK1 such that TBK1 is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of TBK1. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of TBK1.

IPC Classes  ?

• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/52 - Purines, e.g. adenine
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61K 38/07 - Tetrapeptides
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• C07D 471/04 - Ortho-condensed systems

Abstract

The present invention provides compositions and methods of preparing airway cells. In one aspect, an epithelial airway cell derived from an induced pluripotent stem (iPS) cell characterized by expression of airway cell surface markers and an ability to proliferate is described. In another aspect, methods of differentiating an iPS into an epithelial airway cell is provided. Engineered lungs, methods of making such engineered 10 lungs comprising the epithelial airway cells and treating respiratory disorders are also disclosed.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• A61K 35/36 - SkinHairNailsSebaceous glandsCerumenEpidermisEpithelial cellsKeratinocytesLangerhans cellsEctodermal cells

Abstract

Fusion proteins including (a) a mast cell intracellular signaling domain; and (b) an amino acid sequence that is heterologous to the mast cell intracellular signaling domain are provided. In some embodiments, (a) includes the intracellular domain of IgE receptor (FcεRI), a cytokine receptor (c- KIT), a G-protein-coupled receptor, or a toll-like receptor expressed in mast cells, or functional fragment or variant thereof. In some embodiments, the amino acid sequence of (a) includes an ITAM sequence. In preferred embodiments, the fusion proteins are chimeric antigen receptors (referred to as "CAR-mast"), that include a transmembrane domain and an extracellular domain that targets an antigen. Nucleic acids encoding the fusion proteins, and mast cells including or expressing the nucleic acids and/or fusion proteins are also provided, as are methods of the using the same to treat diseases and disorders characterized by expression of the antigen.

IPC Classes  ?

• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C12N 5/0787 - Granulocytes, e.g. basophils, eosinophils, neutrophils or mast cells
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

Abstract

The invention provides a system for hypothermic, restoration and preservation of organs in a mammal. In certain aspects, the system is capable of preserving organs, maintaining cellular integrity and cellular function for hours postmortem or after global ischemia. The invention also provides synthetic organ perfusate formulations, including a novel perfusate autologous blood mixture, which is able to reduce reperfusion injury, stimulate recovery from hypoxia, metabolically support the energy needs of organs and prevent rigor mortis.

IPC Classes  ?

• A01N 1/02 - Preservation of living parts

Abstract

Examples described herein provide a computer-implemented method that includes receiving a noninvasive transabdominal fetal electroencephalography (TA-fEEG) signal associated with a pregnant subject. The method further includes reducing unwanted noise in the TA-fEEG signal using a first machine learning model. The method further includes reconstructing a fetal electroencephalography (fEEG) signal from the TA-fEEG signal using a second machine learning model.

IPC Classes  ?

• A61B 5/291 - Bioelectric electrodes therefor specially adapted for particular uses for electroencephalography [EEG]
• A61B 5/344 - Foetal cardiography
• G06F 18/2134 - Feature extraction, e.g. by transforming the feature spaceSummarisationMappings, e.g. subspace methods based on separation criteria, e.g. independent component analysis
• G06N 3/045 - Combinations of networks

Abstract

The present disclosure provides methods of making and methods of using IL-18 mimic polypeptides for use in therapeutic and non-therapeutic applications. The synthetic IL-18 mimics an increase IL-18R signaling activity even in the presence of an inhibitory molecule such as IL-18BP.

IPC Classes  ?

• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61P 35/00 - Antineoplastic agents
• C07K 14/54 - Interleukins [IL]
• G06G 7/48 - Analogue computers for specific processes, systems, or devices, e.g. simulators
• G06G 7/58 - Analogue computers for specific processes, systems, or devices, e.g. simulators for chemical processes

Abstract

A vacuum-gap optical cavity includes a spacer having a first spacer surface and a second spacer surface, a first mirror having a first reflective coating formed on a first substrate, and a second mirror having a second reflective coating formed on a second substrate. The spacer forms a cavity region that extends between a first aperture at the first spacer surface and a second aperture at the second spacer surface. The first mirror is bonded to the first spacer surface such that the first reflective coating overlaps the first aperture and such that the first mirror completely covers the first aperture. The second mirror is bonded to the second spacer surface such that the second reflective coating overlaps the second aperture and such that the second mirror completely covers the second aperture. The cavity region is maintained under vacuum without active pumping.

IPC Classes  ?

• H01S 3/08 - Construction or shape of optical resonators or components thereof
• H01S 5/10 - Construction or shape of the optical resonator
• G02B 6/293 - Optical coupling means having data bus means, i.e. plural waveguides interconnected and providing an inherently bidirectional system by mixing and splitting signals with wavelength selective means
• H01S 3/13 - Stabilisation of laser output parameters, e.g. frequency or amplitude
• H01S 5/06 - Arrangements for controlling the laser output parameters, e.g. by operating on the active medium
• G02B 5/28 - Interference filters

Abstract

The present invention includes compositions and methods useful for the treatment of chronic vascular inflammation through the inhibition of ACSS2.

IPC Classes  ?

• A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

In various aspects and embodiments the invention provides compositions and methods for facilitating cell penetration of a cargo molecule. In another aspect, the invention provides a method of preventing viral infection in a subject in need thereof, the method comprising providing to the subject a therapeutically effective amount of a polypeptide comprising a cell-penetrating peptide and a retromer binding site.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 31/20 - Antivirals for DNA viruses
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

The description relates to imide-based compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the description provides compounds, which contain on one end a ligand which binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.

IPC Classes  ?

• C07D 495/14 - Ortho-condensed systems
• A61P 35/00 - Antineoplastic agents
• C07D 261/08 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Abstract

Described herein is a method of acquiring a microscopic image of a biological sample. In certain embodiments, the method includes at least one of the following: the method including: embedding the biological sample in a first swellable hydrogel; expanding the first swellable hydrogel and the biological sample embedded therein to obtain a first expanded biological sample; embedding the first expanded biological sample in a second swellable hydrogel; labeling a DNA molecule in a chromatin in the biological sample with a first dye; expanding the second swellable hydrogel and the first expanded biological sample embedded therein to obtain a second expanded biological sample; acquiring the microscopic image of the second expanded biological sample with a light microscopy technology. Also described is a method of evaluating the effect of a treatment of a biological sample using the imaging method.

IPC Classes  ?

• G01N 21/64 - FluorescencePhosphorescence
• G01N 33/483 - Physical analysis of biological material
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• C12Q 1/6813 - Hybridisation assays
• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
• G01N 1/30 - StainingImpregnating
• G01N 1/31 - Apparatus therefor
• G01N 1/36 - Embedding or analogous mounting of samples

Abstract

This invention relates to compositions comprising physiologic dendritic cells and at least one mRNA. The invention further relates to compositions comprising physiologic dendritic cells and at least one mRNA for use in therapeutic treatment.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

This invention relates to compositions comprising physiologic dendritic cells and at least one mRNA. The invention further relates to compositions comprising physiologic dendritic cells and at least one mRNA for use in vaccination.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/12 - Viral antigens

Abstract

Antibodies, chimeric antigen receptors (CARs) and other molecules that specifically bind ENPP3 are provided. Host cells, such as immune cells, including the molecules, antibodies, fusion proteins, CARs, nucleic acids encoding them, are also provided. In some forms, the cells are CAR immune cells. In some forms, the CAR immune cells maintain the ability to kill ENPP3+ cancer cells after multiple stimulations. Pharmaceutical compositions including the antibodies, CARs or T cells are also provided. In some forms, the molecule or antibody includes drugs conjugated thereto, has antibody-dependent cell-mediated cytotoxicity (ADCC) activity, complement-dependent cytotoxicity activity (CDC), and/or is a bi-specific engager optionally a T cell engager or NK cell engager. Methods of using the described molecules to treat ENPP3+ cancers are also described.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61P 35/00 - Antineoplastic agents
• C07K 14/725 - T-cell receptors
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes

Abstract

2A2A-adrenergic receptor agonist and at least one psychedelic agent to treat, ameliorate, or prevent PTSD.

IPC Classes  ?

• A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
• A61K 31/5375 - 1,4-Oxazines, e.g. morpholine
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61P 25/00 - Drugs for disorders of the nervous system
• A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide

Abstract

Described herein is a reverse osmosis system, comprising: a feed source input, a high pressure feed pump fluidly connected to the feed source input, a reverse osmosis (RO) cascade fluidly connected to the high pressure feed pump; wherein the RO cascade comprises at least one low salt rejection reverse osmosis (LSRRO) stage including a LSRRO membrane and a seawater reverse osmosis (SWRO) stage including a SWRO membrane fluidly connected to the at least one LSRRO stage. Described herein is a reverse osmosis system, comprising: a feed source input, a high pressure feed pump fluidly connected to the feed source input, a reverse osmosis (RO) cascade fluidly connected to the high pressure feed pump; wherein the RO cascade comprises at least one low salt rejection reverse osmosis (LSRRO) stage including a LSRRO membrane and a seawater reverse osmosis (SWRO) stage including a SWRO membrane fluidly connected to the at least one LSRRO stage. Also described herein is a reverse osmosis method, comprising: providing the reverse osmosis system of claim 1, inputting a high salinity fluid into the feed source input, increasing the pressure of the high salinity fluid via the high pressure feed pump, performing reverse osmosis via the RO cascade, and collecting at least one of a concentrate and a permeate.

IPC Classes  ?

• B01D 61/58 - Multistep processes
• B01D 61/02 - Reverse osmosisHyperfiltration
• B01D 61/42 - ElectrodialysisElectro-osmosis
• B01D 61/46 - Apparatus therefor
• C02F 1/44 - Treatment of water, waste water, or sewage by dialysis, osmosis or reverse osmosis
• C02F 1/469 - Treatment of water, waste water, or sewage by electrochemical methods by electrochemical separation, e.g. by electro-osmosis, electrodialysis, electrophoresis
• C02F 103/06 - Contaminated groundwater or leachate
• C02F 103/08 - Seawater, e.g. for desalination

Abstract

In various aspects and embodiments the invention provides a method of treating pain, stress and anxiety in a subject in need thereof, wherein the method comprises administering to the subject in need thereof a pharmaceutical composition comprising cannabidiol (CBD) and tetrahydrocannabinol (THC) at a ratio between about 3:1 and about 6:1 CBD:THC.

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients

Abstract

Provided herein are a method of parallelizing zero-knowledge (ZK) protocols, an apparatus for parallelizing zero-knowledge (ZK) protocols, and an apparatus for proving zero-knowledge (ZK) protocols. The method includes providing a ZK framework; calculating local and communication costs for each program instruction of a ZK statement; automatically partitioning the ZK statement according to the calculation; and distributing the partitioned ZK statement to a corresponding number of computing cores for parallel proving or verification. The apparatus for parallelizing zero-knowledge (ZK) protocols includes a processor and a memory unit configured to implement the method. The apparatus for proving zero-knowledge (ZK) protocols includes at least two processors, a memory unit, a communication interface, and a ZK statement parallelized according to the method distributed among the at least two processors. Also provided herein is a non-transitory computer readable storage medium storing computer-executable instructions for performing the method.

IPC Classes  ?

• H04L 9/32 - Arrangements for secret or secure communicationsNetwork security protocols including means for verifying the identity or authority of a user of the system
• G06F 9/28 - Enhancement of operational speed, e.g. by using several microcontrol devices operating in parallel
• G06Q 20/38 - Payment protocolsDetails thereof

Abstract

A programmably reconfigurable Ising machine. In embodiments, the programmably reconfigurable Ising machine includes a plurality of spin circuits and a reconfigurable routing network. Each spin circuit includes a spin generator and a set of reconfigurable coupling blocks operatively connected to the spin generator. In embodiments, each reconfigurable coupling block includes a coupling switch operatively connected to the spin generator, a variable coupling unit operatively connected to the coupling switch, and a pin operably connected to the variable coupling unit. In embodiments, the coupling switch and the variable coupling unit are connected to memory and are configurable based on a configuration stored in the memory. In embodiments, the reconfigurable routing network is configured to selectively operatively connect two or more spin circuit of the programmably reconfigurable Ising machine via reconfigurable coupling blocks. Connected spin circuits are interdependent.

IPC Classes  ?

• H03K 19/17728 - Reconfigurable logic blocks, e.g. lookup tables
• G06F 17/11 - Complex mathematical operations for solving equations
• G06N 5/01 - Dynamic search techniquesHeuristicsDynamic treesBranch-and-bound
• G06N 10/00 - Quantum computing, i.e. information processing based on quantum-mechanical phenomena

Abstract

The present application provides pharmaceutical compositions and methods for treating diseases or disorders. The pharmaceutical composition comprises N-methyl-D-aspartate receptor modulator and μ-opioid receptor modulator. The present application also discloses formulations, dosing and administration routes for the pharmaceutical composition. Diseases can be treated by the pharmaceutical composition are also described.

IPC Classes  ?

• A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61P 25/24 - Antidepressants
• A61P 25/32 - Alcohol-abuse

Abstract

Methods and compositions for treating or preventing non-viral tick-borne diseases and symptoms thereof by administering a long half-life 8-aminoquinoline, such as tafenoquine, are disclosed. Kits including a means for testing for a non-viral tick-borne disease and/or symptoms thereof and a long half-life 8-aminoquinoline, such as tafenoquine, are disclosed.

IPC Classes  ?

• A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 31/4706 - 4-Aminoquinolines8-Aminoquinolines, e.g. chloroquine, primaquine
• A61K 31/33 - Heterocyclic compounds

Abstract

In various aspects and embodiments the invention provides a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising an effective amount of a cytoskeletal tension regulator and an effective amount of a polypeptide having 80% or greater sequence identity to SEQ ID NO: 1 Fas Ligand (FasL).

IPC Classes  ?

• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61K 38/19 - CytokinesLymphokinesInterferons
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The invention features a composition comprising a potent cytotoxic compound and a pHILIP® peptide, where, e.g., the cytotoxic compound cannot be used alone due to a lack of targeting. pHILIP® peptide targets cytotoxic compounds to acidic diseased tissue, translocates cytotoxic compounds across plasma membranes into the cytosols of cells in acidic diseased tissues and induces cell death predominantly in the targeted acidic diseased tissue.

IPC Classes  ?

• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
• A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• A61K 38/12 - Cyclic peptides
• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• A61P 35/00 - Antineoplastic agents

Abstract

Embodiments of the present invention comprises one or more of an article composed of a copolymer, a copolymer made from a process, and a process for the preparation of a copolymer composition by metal free enzyme ring-opening polymerization of a monomer composition comprising i) an ethylene brassylate monomer; ii) a 1-4 dioxan-2-one (DO); iii) lipase B from Candida antarctica (Novozyme® 435) and at an elevated temperature, processing the monomer reactants i) and ii) to a copolymer via ring-opening polymerization under solvent-free conditions and a nitrogen atmosphere in the absence of a metal and the presence of the lipase to produce a random EB-co-DO copolymer.

IPC Classes  ?

• C08G 63/08 - Lactones or lactides
• A61L 27/18 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances
• A61L 27/58 - Materials at least partially resorbable by the body

Abstract

Provided herein are compositions and methods of treating and/or preventing amyotrophic lateral sclerosis (ALS) in a subject in need thereof, the methods comprising administering an agent wherein the agent modifies neurons via changes in Kcnn1 protein expression or activity, which in turn modifies neuron firing and/or increases the clearance or protection from toxicity of an ALS-causing protein.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links

Abstract

The present invention relates to a decellularized extracellular matrix (ECM), wherein the ECM originates from a tissue lacking thrombospondin-2 (TSP2). The invention further relates to compositions and methods for promoting tissue regeneration in a subject by administering a decellularized extracellular matrix (ECM), wherein the ECM originates from a tissue lacking thrombospondin-2 (TSP2). The invention further provides methods for preparing a decellularized extracellular matrix (ECM), wherein the ECM originates from a tissue lacking thrombospondin-2 (TSP2).

IPC Classes  ?

• A61K 35/32 - BonesOsteocytesOsteoblastsTendonsTenocytesTeethOdontoblastsCartilageChondrocytesSynovial membrane
• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
• A61L 27/52 - Hydrogels or hydrocolloids
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Abstract

The present disclosure provides compositions and methods comprising variant polypeptides of IL-12 with partial agonism relative to wild-type IL-12 for use in therapeutic and non-therapeutic applications.

IPC Classes  ?

• A61K 38/20 - Interleukins
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 35/00 - Antineoplastic agents

Abstract

The present disclosure provides, in one aspect, bifunctional compounds that can be used to promote or enhance degradation of certain circulating proteins. In certain embodiments, the circulating protein mediates a disease and/or disorder in a subject, and treatment or management of the disease and/or disorder requires degradation, removal, or reduction in concentration of the circulating protein in the subject. Thus, in certain embodiments, administration of a compound of the disclosure to the subject removes or reduces the circulation concentration of the circulating protein, thus treating, ameliorating, or preventing the disease and/or disorder.

IPC Classes  ?

• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment

Abstract

The present invention provides compounds and methods for treating MKP-5 modulated disease. In certain embodiments, the MKP-5 modulated disease is a fibrotic disease.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• C07D 239/78 - QuinazolinesHydrogenated quinazolines with hetero atoms directly attached in position 2
• C07D 471/04 - Ortho-condensed systems
• C07D 491/052 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
• C07D 495/04 - Ortho-condensed systems

Abstract

The present invention provides compositions and methods for treating diseases or disorders using a therapeutically effective amount of a rapid-acting antidepressant (RAAD) and a therapeutically effective amount of a mTOR inhibitor and/or immunosuppressant. In certain embodiments, the RAAD and the mTOR inhibitor and/or immunosuppressant are part of a single pharmaceutical composition.

IPC Classes  ?

• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions
• A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 25/24 - Antidepressants

Abstract

Catalysts for selective oxidation of methane and methods of making and using thereof have been developed. The catalysts can be incorporated into reactors which allow for the capture and oxidation of methane from gas streams, such as by photochemical means.

IPC Classes  ?

• B01D 53/94 - Chemical or biological purification of waste gases of engine exhaust gases by catalytic processes
• B01J 21/06 - Silicon, titanium, zirconium or hafniumOxides or hydroxides thereof
• B01J 23/06 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of zinc, cadmium or mercury
• B01J 23/08 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of gallium, indium or thallium
• B01J 23/34 - Manganese
• B01J 23/42 - Platinum
• B01J 23/50 - Silver
• B01J 27/04 - Sulfides
• B01J 27/14 - PhosphorusCompounds thereof
• F01N 3/10 - Exhaust or silencing apparatus having means for purifying, rendering innocuous, or otherwise treating exhaust for rendering innocuous by thermal or catalytic conversion of noxious components of exhaust
• B01J 23/44 - Palladium
• B01J 23/18 - Arsenic, antimony or bismuth
• B01J 23/22 - Vanadium
• B01J 37/02 - Impregnation, coating or precipitation

Abstract

The present invention provides compositions and methods comprising an activator of interleukin-18 (IL-18) activity for use in therapeutic and non-therapeutic applications. The activator provides IL-18 signaling activity even in the presence of an inhibitory molecule 5 such as IL-18 binding protein (IL-18BP).

IPC Classes  ?

• A61K 38/20 - Interleukins
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 35/768 - Oncolytic viruses not provided for in groups
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61P 35/00 - Antineoplastic agents
• C07K 14/54 - Interleukins [IL]
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

A pediatric dosage form for dosing ultra-low doses of an active pharmaceutical ingredient having a plurality of pellets where each pellet consists essentially of a coating of tyrosine kinase inhibitor over a nonpareil seed. The tyrosine kinase inhibitor coated nonpareils are coated thereon with a coating consisting essentially of hydroxypropyl methylcellulose. The active coated beads according to the invention allows for human subject dosing on a mg/kg basis. The sum of such pellets contained within a capsule forming a single dosage unit of an ultra-low dose of tyrosine kinase inhibitor.

IPC Classes  ?

• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/50 - Microcapsules
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Abstract

The present disclosure relates, in part, to therapeutic agent- or polymeric macromolecule-conjugated compounds of formula (I). In certain embodiments, the compounds of the present disclosure possess high affinity and/or specificity for certain cell types. In another aspect, the present disclosure provides a method of treating, preventing, and/or ameliorating cancer and/or ocular diseases in a subject. In another aspect, the present disclosure provides a method of delivering a therapeutic agent across a blood-brain and/or blood-retinal barrier of a subject.

IPC Classes  ?

• C07D 311/82 - Xanthenes
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• C09B 11/28 - Pyronines
• G01N 21/64 - FluorescencePhosphorescence
• A61P 35/00 - Antineoplastic agents

Abstract

Disclosed herein are methods of delivering a compound into a cell. In some embodiments, the method includes expressing in the cell a protein that confers a receptiveness for a compound herein, as well as contacting the cell with the compound herein. Also disclosed herein are kit for performing the method. In certain embodiments, the method and the kit are method and kit for performing gene therapy in a subject.

IPC Classes  ?

• A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
• A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/33 - Heterocyclic compounds

Abstract

Reinforced external graft support assemblies and methods of manufacture and implantation are provided herein. In particular, graft support assemblies are composed of single or multilayer sheaths designed to provide mechanical support to vascular conduits during cardiovascular bypass surgery. Graft sheath systems may be fabricated using 3D printing techniques with biocompatible materials incorporate surgical design considerations such as mechanical strength, flexibility, porosity, and the ability to be tailored to specific anatomical structures. External graft sheaths may include one or more layers of various biomaterials to produce customized biomechanical properties including varied time courses of degradation. Furthermore, these customizable features may incorporate standardized designs or be tailored for individual patients depending on medical and surgical history, or other pertinent geometric attributes measured in pre-operative medical imaging. These methods protect vascular conduits, particularly venous grafts, from adverse remodeling and graft failure, thereby providing precision medicine solutions to cardiovascular bypass surgery.

IPC Classes  ?

• A61F 2/86 - Stents in a form characterised by wire-like elementsStents in a form characterised by a net-like or mesh-like structure
• A61F 2/07 - Stent-grafts
• A61F 2/78 - Means for protecting prostheses or for attaching them to the body, e.g. bandages, harnesses, straps, or stockings for the limb stump
• B33Y 80/00 - Products made by additive manufacturing

Abstract

in vivo in vivo. Typically, the masking domain is removed by protease present in the TME. The compositions and methods provide enhanced ACT for cancer, auto-immune disease and other disease and disorders. Also disclosed are hmABs, genetically modified cells and pharmaceutical compositions and methods of use thereof for treating subjects having diseases or disorders.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• C07K 14/70 - Enkephalins
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 15/86 - Viral vectors

Abstract

The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.

IPC Classes  ?

• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 38/05 - Dipeptides
• A61K 38/06 - Tripeptides
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 207/26 - 2-Pyrrolidones
• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems
• C07J 43/00 - Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta[a]hydrophenanthrene skeleton
• C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes

Abstract

coin vitro in vivo in vivo methods of using the particles, macroimplants, and compositions thereof, in drug delivery platforms and gene editing platforms.

IPC Classes  ?

• C08G 63/02 - Polyesters derived from hydroxy carboxylic acids or from polycarboxylic acids and polyhydroxy compounds

Abstract

i.e.i.e., bolus and continuous infusion) of dimethyltryptamine (DMT) to the subject. The present disclosure further relates to kits useful for performing the methods described herein.

IPC Classes  ?

• C07D 209/16 - Tryptamines
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
• A61P 26/24 -

Abstract

The present disclosure provides antibody oligonucleotide conjugates having a 3E10 antibody or an antigen binding fragment thereof conjugated to a single stranded oligonucleotide that may hybridize to an acceptor splice site, a donor splice site, or an exonic splice enhancer element of a pre-mRNA transcript. Compositions including the antibody oligonucleotide conjugates and methods of using the antibody oligonucleotide conjugates are also provided.

IPC Classes  ?

• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

The present disclosure relates, in one aspect, to a method of treating, preventing, and/or ameliorating cancer in a subject with administration of PF-05175157, or a salt or solvate thereof. In another aspect, the present disclosure relates to a method of treating preventing, and/or ameliorating cancer in a subject with administration of an acetyl-CoA carboxylase 1 and/or 2 inhibitor (ACCi) and at least one additional agent. In certain embodiments, the cancer is breast cancer.

IPC Classes  ?

• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/04 - Antineoplastic agents specific for metastasis

Abstract

Rubia cordifolia Rubia cordifolia plant are potent inhibitors of a range of receptors and protein implicated in the pathology of a number of common diseases and disorders. In certain embodiments, the method of the present invention are useful for treating at least one disease or disorder related to a steroid hormone receptor. In other embodiments, the methods are useful for treating at least one disease or disorder related to the expression of at least one protein selected from the group consisting of Brd4, Brd2, cyclin D1, and Gata3.

IPC Classes  ?

• A61K 36/74 - Rubiaceae (Madder family)
• A61K 38/00 - Medicinal preparations containing peptides
• C07K 7/00 - Peptides having 5 to 20 amino acids in a fully defined sequenceDerivatives thereof
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 7/64 - Cyclic peptides containing only normal peptide links
• A61P 35/00 - Antineoplastic agents

Abstract

Superconducting composite materials and methods for making superconducting composite materials are described herein. Superconducting composite materials include a confining material and an intercalant material, and can include particles intercalated in the confining material. The confining material induces a pressure in the intercalant material. The intercalated particles, if included, induce strain on the confining material, which is then transmitted to the intercalant material increasing the induced pressure. A superconducting structure of the intercalant material produced when the intercalant material is exposed to high pressure is stabilized by the induced pressure enabling preservation of superconducting behavior at least in part or in full at ambient pressure.

IPC Classes  ?

• H10N 60/85 - Superconducting active materials
• C01B 32/158 - Carbon nanotubes
• C01B 32/198 - Graphene oxide
• H01L 23/532 - Arrangements for conducting electric current within the device in operation from one component to another including external interconnections consisting of a multilayer structure of conductive and insulating layers inseparably formed on the semiconductor body characterised by the materials

Abstract

The present disclosure includes compositions and methods for treating, ameliorating, and/or preventing certain diseases and/or disorders associated with associated with DNAse1 and/or DNAse1L3 deficiency.

IPC Classes  ?

• C12N 9/22 - Ribonucleases
• C07K 19/00 - Hybrid peptides
• A61K 38/46 - Hydrolases (3)
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 38/43 - EnzymesProenzymesDerivatives thereof

Abstract

In one aspect, the present disclosure relates to an imaging agent comprising a detectable moiety covalently bound or coordinated to a “Moiety A” selected from a peptide, a chelator, or an organic compound comprising a leaving atom or a leaving group that can be substituted with a radioisotope. “Moiety A” is covalently bound to a flexible linker which is further covalently bound to a polypeptide of between 2 and 20 glycine-proline-hydroxyproline repeats. In certain embodiments, the detectable moiety comprises a radioisotope or metal. In another aspect, the disclosure relates to a method of using the imaging agents of the present disclosure to detect collagen turnover in a subject.

IPC Classes  ?

• A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• A61B 6/03 - Computed tomography [CT]
• A61B 6/42 - Arrangements for detecting radiation specially adapted for radiation diagnosis
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 51/08 - Peptides, e.g. proteins
• C07K 4/00 - Peptides having up to 20 amino acids in an undefined or only partially defined sequenceDerivatives thereof